AR033832A1 - Un metodo ex vivo para diagnosticar una enfermedad autoinmune, anticuerpo, composicion de diagnostico que lo comprende, y usos del anticuerpo - Google Patents
Un metodo ex vivo para diagnosticar una enfermedad autoinmune, anticuerpo, composicion de diagnostico que lo comprende, y usos del anticuerpoInfo
- Publication number
- AR033832A1 AR033832A1 ARP010103870A ARP010103870A AR033832A1 AR 033832 A1 AR033832 A1 AR 033832A1 AR P010103870 A ARP010103870 A AR P010103870A AR P010103870 A ARP010103870 A AR P010103870A AR 033832 A1 AR033832 A1 AR 033832A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibody
- peptide
- drb1
- mhc
- antibodies
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 abstract 4
- 102100038823 RNA-binding protein 45 Human genes 0.000 abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 230000001363 autoimmune Effects 0.000 abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 2
- 108010029657 HLA-DRB1*04:01 antigen Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Rehabilitation Therapy (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Un método ex vivo para diagnosticar una enfermedad autoinmune que comprende detectar la presencia de un complejo MHC-péptido específico autoinmune en un paciente que presenta una enfermedad autoinmune con anticuerpos o dominios que ligan antígenos de los mismos que se ligan específicamente a un complejo MHC-péptido derivado de HC-gp39. Anticuerpos monoclonales usados en el método; composición para diagnóstico que comprende uno o más de los anticuerpos y un agente de detección; uso del anticuerpo para la elaboración de un preparado farmacéutico para el tratamiento de trastornos autoinmunes; y uso del anticuerpo para la purificación de complejos MHC-péptido específicos autoinmunes. El complejo MHC-péptido a ser detectado de acuerdo con la presente invención se asocia con enfermedades autoinmunes, preferentemente con artritis reumatoide. Preferentemente, el complejo MHC es del tipo HLA DRB1*0401, DRB1*0404, DRB1*0407 y DRB1*0101 siendo el HLA DRB1*0401 es que más se prefiere mientras que el péptido en el complejo es preferentemente un antígeno asociado con artritis reumatoide. Preferentemente los anticuerpos son preparados usando complejos de péptidos derivados de HC gp-39. Preferentemente el péptido comprende los aminoácidos 263-273 o 263-275 de HC gp-39 (HC gp-39263-273 o HC gp-39263-275). Los anticuerpos también pueden ser usados para propósitos terapéuticos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00202844 | 2000-08-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR033832A1 true AR033832A1 (es) | 2004-01-07 |
Family
ID=8171913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010103870A AR033832A1 (es) | 2000-08-14 | 2001-08-13 | Un metodo ex vivo para diagnosticar una enfermedad autoinmune, anticuerpo, composicion de diagnostico que lo comprende, y usos del anticuerpo |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7320873B2 (es) |
| EP (1) | EP1319184B1 (es) |
| JP (1) | JP2004506901A (es) |
| CN (1) | CN1305906C (es) |
| AR (1) | AR033832A1 (es) |
| AT (1) | ATE368225T1 (es) |
| AU (2) | AU9373501A (es) |
| BR (1) | BR0113213A (es) |
| CA (1) | CA2415353A1 (es) |
| DE (1) | DE60129572T2 (es) |
| ES (1) | ES2290171T3 (es) |
| IL (2) | IL154000A0 (es) |
| MX (1) | MXPA03001391A (es) |
| WO (1) | WO2002014870A2 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214373B2 (en) | 2001-07-24 | 2007-05-08 | Yale University | Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease |
| AU2005247950B2 (en) * | 2004-05-27 | 2012-02-02 | Receptor Logic, Inc. | Antibodies as T cell receptor mimics, methods of production and uses thereof |
| EP1933864A4 (en) * | 2005-09-07 | 2009-12-16 | Receptor Logic Ltd | ANTIBODIES AS T-CELL RECEPTOR MIMICS, METHOD OF MANUFACTURE AND ITS USES |
| EP2124987A4 (en) * | 2007-01-19 | 2012-05-02 | Kai Pharmaceuticals Inc | METHOD OF USE OF EPSILON HEMMER COMPOUNDS FOR PAIN LIFTING |
| WO2009151487A1 (en) * | 2008-06-13 | 2009-12-17 | Receptor Logic, Inc. | Methods of assaying vaccine potency |
| WO2010141658A1 (en) * | 2009-06-04 | 2010-12-09 | The Regent Of The University Of Colorado | Therapeutic compositions and methods for the prevention of autoimmune diseases |
| AU2011223660B2 (en) * | 2010-03-02 | 2016-10-13 | Novelmed Therapeutics, Inc. | A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit C5 interactions with properdin |
| EP2593480A2 (en) * | 2010-07-15 | 2013-05-22 | Technion Research & Development Foundation Ltd. | Antibodies with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides |
| EP2593551B1 (en) | 2010-07-15 | 2016-09-14 | Technion Research & Development Foundation Ltd. | Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides |
| US20130302329A1 (en) * | 2010-09-21 | 2013-11-14 | Trustees Of Boston University | Diagnostic tests for immune reactivity with human endothelial cell growth factor |
| CN103476258B (zh) | 2011-02-25 | 2017-04-26 | 默沙东公司 | 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物 |
| WO2012162697A1 (en) | 2011-05-26 | 2012-11-29 | The Regents Of The University Of Colorado, A Body Corporate | Compounds that modulate autoimmunity and methods of using the same |
| US9926366B2 (en) | 2012-10-04 | 2018-03-27 | Novelmed Therapeutics, Inc. | Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies |
| EP3152235B1 (en) | 2014-05-29 | 2021-08-25 | MacroGenics, Inc. | Tri-specific binding molecules and methods of use thereof |
| EP3247384B1 (en) | 2015-01-14 | 2023-10-04 | The Regents of the University of Colorado, a body corporate | In vitro method of diagnosis of type 1 diabetes with insulin mimotopes |
| CA3018727C (en) | 2016-03-24 | 2024-03-26 | The Regents Of The University Of Colorado, A Body Corporate | Methods of treating autoimmune disease |
| CN110325209A (zh) | 2017-02-24 | 2019-10-11 | 宏观基因有限公司 | 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途 |
| US11052060B2 (en) | 2018-02-12 | 2021-07-06 | The Regents Of The University Of Colorado, A Body Corporate | Compounds and methods for treating autoimmunity |
| US11013707B2 (en) | 2018-03-23 | 2021-05-25 | The Regents Of The University Of Colorado, A Body Corporate | Administration of oral methyldopa |
| CN111423504B (zh) * | 2020-04-17 | 2021-03-26 | 安徽高安生物医学科技有限公司 | 黑色素瘤特异性抗原肽、肽复合物以及人工抗原呈递细胞 |
| CN115960239B (zh) * | 2023-01-03 | 2025-10-17 | 陕西脉元生物科技有限公司 | 特异性识别hcgp-39的单克隆抗体及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2103770T3 (es) | 1990-11-26 | 1997-10-01 | Akzo Nobel Nv | Procedimiento de produccion de anticuerpos monoclonales. |
| WO1995002188A1 (en) | 1993-07-12 | 1995-01-19 | The Regents Of The University Of California | Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices |
| CA2164498C (en) * | 1993-07-09 | 2007-09-11 | Paul A. Price | Assay for ykl-40 as a marker for degradation of mammalian connective tissue matrices |
| WO1998012221A1 (de) * | 1996-09-18 | 1998-03-26 | Gerhild Wildner | Peptide als diagnostikum und therapeutikum für autoimmunerkrankungen |
| IL122233A (en) | 1996-12-06 | 2001-04-30 | Akzo Nobel Nv | Method of generating monoclonal antibodies to cell wall and pharmaceutical preparations and diagnostic agents containing them |
-
2001
- 2001-08-08 JP JP2002519948A patent/JP2004506901A/ja not_active Withdrawn
- 2001-08-08 CA CA002415353A patent/CA2415353A1/en not_active Abandoned
- 2001-08-08 AU AU9373501A patent/AU9373501A/xx active Pending
- 2001-08-08 US US10/344,872 patent/US7320873B2/en not_active Expired - Fee Related
- 2001-08-08 AT AT01974130T patent/ATE368225T1/de not_active IP Right Cessation
- 2001-08-08 MX MXPA03001391A patent/MXPA03001391A/es active IP Right Grant
- 2001-08-08 DE DE60129572T patent/DE60129572T2/de not_active Expired - Fee Related
- 2001-08-08 WO PCT/EP2001/009136 patent/WO2002014870A2/en not_active Ceased
- 2001-08-08 AU AU2001293735A patent/AU2001293735B2/en not_active Ceased
- 2001-08-08 IL IL15400001A patent/IL154000A0/xx unknown
- 2001-08-08 EP EP01974130A patent/EP1319184B1/en not_active Expired - Lifetime
- 2001-08-08 CN CNB018141935A patent/CN1305906C/zh not_active Expired - Fee Related
- 2001-08-08 ES ES01974130T patent/ES2290171T3/es not_active Expired - Lifetime
- 2001-08-08 BR BR0113213-0A patent/BR0113213A/pt not_active IP Right Cessation
- 2001-08-13 AR ARP010103870A patent/AR033832A1/es active IP Right Grant
-
2003
- 2003-01-16 IL IL154000A patent/IL154000A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE368225T1 (de) | 2007-08-15 |
| CN1447919A (zh) | 2003-10-08 |
| EP1319184A2 (en) | 2003-06-18 |
| IL154000A (en) | 2010-02-17 |
| CN1305906C (zh) | 2007-03-21 |
| CA2415353A1 (en) | 2002-02-21 |
| DE60129572T2 (de) | 2008-04-17 |
| US7320873B2 (en) | 2008-01-22 |
| EP1319184B1 (en) | 2007-07-25 |
| AU9373501A (en) | 2002-02-25 |
| ES2290171T3 (es) | 2008-02-16 |
| JP2004506901A (ja) | 2004-03-04 |
| AU2001293735B2 (en) | 2006-05-25 |
| WO2002014870A2 (en) | 2002-02-21 |
| BR0113213A (pt) | 2003-07-08 |
| WO2002014870A3 (en) | 2002-08-15 |
| IL154000A0 (en) | 2003-07-31 |
| DE60129572D1 (de) | 2007-09-06 |
| US20040137514A1 (en) | 2004-07-15 |
| MXPA03001391A (es) | 2004-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR033832A1 (es) | Un metodo ex vivo para diagnosticar una enfermedad autoinmune, anticuerpo, composicion de diagnostico que lo comprende, y usos del anticuerpo | |
| Nossal et al. | Antigens, lymphoid cells and the immune response | |
| KR920700674A (ko) | 특정 t세포 집단에 의한 발명 반응으로부터 야기되는 질병에 대한 예방접종 및 방법 | |
| Spitler et al. | Studies on the immune response to a characterized antigenic determinant of the tobacco mosaic virus protein | |
| Dendle et al. | Pneumococcal vaccination in adult solid organ transplant recipients: A review of current evidence | |
| ES2180754T3 (es) | Compuestos y metodos para la deteccion de infeccion por t. cruzi. | |
| BR9917218A (pt) | Anticorpos monoclonais, antìgenos, e diagnósticoe terapia de doenças malignas | |
| BR0112602A (pt) | Compostos e métodos para tratamento e diagnóstico de infecção clamidial | |
| BR0016066A (pt) | Compostos e métodos para tratamento e diagnóstico de infecção clamidial | |
| BR0207067A (pt) | Método para identificar, isolar e produzir antìgenos para um patógeno especìfico e uso do mesmo | |
| DE59705683D1 (de) | IMMUNOLOGISCHES NACHWEISVERFAHREN VON ANTIKÖRPERN, DIE GEGEN GEWEBE-TRANSGLUTAMINASE (tTG) GERICHTET SIND, VERWENDUNG VON tTG ZUR DIAGNOSE UND THERAPIEKONTROLLE SOWIE ORALES PHARMAZEUTISCHES MITTEL ENTHALTEND tTG | |
| BR9815289A (pt) | Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado | |
| DE69638024D1 (de) | Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren | |
| DE69333076D1 (de) | Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis | |
| Khan et al. | Induction of antigen-specific human cytotoxic T cells by Toxoplasma gondii. | |
| PT100978A (pt) | Peptidos recombitopos, sequencias de acidos nucleicos que os codificam, composicoes terapeuticas que os contem e seu uso | |
| SE7809249L (sv) | Antigen for tidig graviditetsprovning och kontraceptivt vaccin | |
| DE60029953D1 (de) | Spezifische antikörper gegen humanes choriongonadotropin hormone und deren verwendung in therapie und diagnose | |
| Yu et al. | Development of a candidate vaccine against Ross River virus infection | |
| Bošnjaković et al. | Radiolabelled anti-human fibrin antibody: a new thrombus-detecting agent | |
| Iraqi | Diagnostic value of semi-purified antigens of hydatid cyst fluid in human cystic echinococcosis | |
| JPH05508220A (ja) | 抗ＩｇＥ自己抗体の検出および調製法およびこれら抗体の診断および治療組成物中での活性剤としての使用 | |
| Gore et al. | A soluble antigen fluorescent antibody (SAFA) test for the immunodiagnosis of trichinosis in man and experimental animals | |
| Coleman | Protein haptenation by drugs. | |
| Zabriskie et al. | The role of heart binding antibodies in rheumatic fever |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |